

Contents

Appendix A: Acknowledgments 1

Appendix B: Evidence on Hormone Replacement Therapy and Fractures 5

References 17

Appendix C: Evidence on HRT and Bone Loss 19

Conclusions 30

References 31

Appendix D: Summary of Hip Fracture Prediction Methods 35

Requirements of the OTA Hip Fracture Prediction Model **35**

Measuring Bone Mass 35

Predicting Bone Mass Over Time 36

Relationship of Bone Mass to Hip Fracture Risk 44

References 47

Appendix E: Hormonal Replacement Therapy Regimens 49

Estrogen Dosing Regimens 49

Therapy with PERT 53

Acute Indications for HRT 54

Evaluation and Followup of Women Taking HRT 55

Compliance with HRT **56**

References 59

Appendix F: Evidence on Breast Cancer and Hormonal Replacement Therapy 65


Biological Plausibility **65**

Case-Control Studies **66**

Cohort Studies 67

Clinical Trials **68**

Combined Estrogen-Progestin Therapy and Breast Cancer Risk **68**



Stage of Breast Cancer at Diagnosis in HRT Users
Versus Nonusers 70
Breast Cancer Mortality in HRT Users Versus
Nonusers 71
Conclusions **72**
References 73

Appendix G: Evidence on HRT and Endometrial Cancer 111

Duration and Dose of Estrogen 112
Recency of Use of Estrogen 112
Stage and Grade of Endometrial Cancer 112
Estrogen Use and Survival from Endometrial
Cancer 114
Estrogen/Progestin Replacement Therapy 115
Implications for OTA's Cost Effectiveness Model 117
References 118

Appendix H: Evidence on HRT and Gallbladder Disease 159

References 165

Appendix 1: Evidence on HRT and Coronary Heart Disease 167

How Estrogen May Affect CHD 167
Evidence on ERT and CHD 168
Evidence on PERT and CHD 189
Conclusions 191
References 193

Appendix J: Methods for Estimating costs 201

BMD Screening Cost 201
HRT Cost 201
Cost of Heart Disease 204
Cost of Hip Fracture 205
Cost of Cholecystectomy 205
Breast Cancer Costs 205
Endometrial Cancer Costs 207
References 210

Appendix K: Abbreviations and Glossary 211